Advances in Pharmacoepidemiology and Drug Safety

Drug reaction with eosinophilia and systemic symptoms (DRESS) with Teicoplanin: A case report

11^th International Conference on Pharmacoepidemiology and Clinical Research

October 02-03, 2017 Kuala Lumpur, Malaysia

Kheirollah Gholami, Mehdi Mohammadi and Sholeh Ebrahimpour

Tehran University of Medical Sciences, Iran

Posters & Accepted Abstracts: Adv Pharmacoepidemiol Drug Saf

Abstract:

Intramuscular Teicoplanin (400 mg three doses every 12 hours, then 400 mg daily, intramuscularly) was prescribed for a 37-year-old woman with presumptive diagnosis of cellulitis. On the 14th day of treatment, she developed generalized maculopapular rash, accompanied by fever, wheezing, shortening of breath and lymphadenopathy. Lab tests revealed abnormal liver enzymes, leukocytosis and eosinophilia. The treatment was interrupted with suspicion of drug reaction. Fever subsided after 48 hours. Skin eruption and respiratory symptoms began to resolve within 2 weeks. The follow-up lab tests performed 1 month later indicated resolution of liver dysfunction. With respect to delayed onset of symptoms including fever, generalized rash, lymphadenopathy and organ involvement, drug reaction with eosinophilia and systemic symptoms (DRESS) was highly suspected. The causality was evaluated by conventional scoring systems. The reaction was rated as probable (score=5) according to RegiSCAR and possible (score=5) based on Kardaun et al. scoring system. However, DRESS was not confirmed by the Japanese group�??s criteria for diagnosis of DRESS/drug-induced hypersensitivity syndrome (DIHS).